Please login to the form below

Not currently logged in
Email:
Password:

DBV Technologies

This page shows the latest DBV Technologies news and features for those working in and with pharma, biotech and healthcare.

FDA knocks back DBV’s peanut allergy therapy once again

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... The setback means that DBV’s drug loses further ground

Latest news

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    California biotech Aimmune has been in a race to market with rival companies like France’s DBV Technologies, which filed for approval of its Viaskin Peanut skin patch-based product at ... DBV’s share price in the last few weeks.

  • Aimmune gets FDA panel backing for peanut allergy therapy Aimmune gets FDA panel backing for peanut allergy therapy

    of rivals including DBV Technologies which has a patch-based immunotherapy product in late-stage development. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... DBV says its new filing “incorporates additional data needs on

  • Aimmune wins over ICER for peanut allergy product Aimmune wins over ICER for peanut allergy product

    Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the marketing application for its Viaskin Peanut patch ... DBV has said it intends to refile with the US agency

  • Aimmune preps EU filing for peanut allergy immunotherapy Aimmune preps EU filing for peanut allergy immunotherapy

    The regulatory timeframe outs Aimmune ahead of French biotech DBV Technologies – which is gearing up to refile its Viaskin Peanut candidate later this year in the US having had to withdraw

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics